Cover Image
市場調查報告書

慢性阻塞性肺病(COPD)治療藥的全球市場:2016∼2020年

Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 364923
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病(COPD)治療藥的全球市場:2016∼2020年 Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020
出版日期: 2016年07月20日 內容資訊: 英文 107 Pages
簡介

慢性阻塞性肺病是慢性的支氣管炎和肺氣腫的症狀組合,慢性支氣管炎導致細微支氣管的發炎,肺氣腫是肺泡牆遭破壞,造成呼吸困難。全球慢性阻塞性肺病治療藥市場,預計2016∼2020年以4.85%的年複合成長率擴大。

本報告提供全球慢性阻塞性肺病(COPD)治療藥市場相關調查,市場成長預測,各地區趨勢,市場趨勢與課題,主要供應商的競爭趨勢等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 開發平台分析

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 慢性阻塞性肺病治療藥的購買標準

第8章 慢性阻塞性肺病治療藥的全球市場:各類藥物市場分類

  • 聯合治療
  • 支氣管擴張劑
  • 類固醇
  • 白三烯拮抗劑
  • PDE-4抑制劑
  • 其他

第9章 慢性阻塞性肺病治療藥的全球市場:各給藥途徑分類

  • 吸入
  • 口服

第10章 慢性阻塞性肺病治療藥的藥物輸送設備市場

  • 市場概要
  • 各產品類型市場分類

第11章 慢性阻塞性肺病治療藥的全球市場:各地區分類

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 中國

第12章 慢性阻塞性肺病治療藥的全球市場:促進要素

  • 抽煙
  • LABA/LAMA的聯合治療的攝取
  • 一時性治療藥認證造成的堅固開發平台

第13章 促進要素的影響

第14章 慢性阻塞性肺病治療藥的全球市場:課題

  • 開發平台分子的技術創新不足
  • 對控制器治療藥的使用的懈怠
  • 低的診斷率

第15章 促進要素與課題的影響

第16章 慢性阻塞性肺病治療藥的全球市場:趨勢

第17章 供應商環境

  • 競爭模式
  • 主要消息

第18章 主要供應商分析

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Novartis
  • Teva Pharmaceuticals
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

目錄
Product Code: IRTNTR9968

About Chronic Obstructive Pulmonary Disease (COPD)

COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.

Technavio's analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
  • Teva

Other Prominent Vendors

  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • Asmacure
  • Astellas Pharma
  • BioMarck Pharmaceuticals
  • Chiesi Farmaceutici
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Innoviva
  • Invion
  • MediciNova
  • Mereo BioPharma
  • Mylan
  • Orion Corporation
  • Palobiofarma
  • Pearl Therapeutics
  • Pharmaxis
  • Prosonix
  • Pulmagen Therapeutics
  • RespiVert
  • SolAeroMed
  • Sunovion Pharmaceuticals
  • Theravance Biopharma
  • Theron Pharmaceuticals
  • Verona Pharma
  • Xention
  • Yungjin Pharm
  • ZAI Lab

Market driver

  • Uptake of LABA/LAMA combination therapies
  • For a full, detailed list, view our report

Market challenge

  • Negligence toward use of controller medications
  • For a full, detailed list, view our report

Market trend

  • Increased adoption of e-cigarettes and smoking cessation products
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Breakthrough in COPD research
  • COPD: An overview

PART 05: Pipeline analysis

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Key buying criteria for COPD drugs

PART 08: Market segmentation by drug class

  • Combination therapies
  • Bronchodilators
  • Steroids
  • Leukotriene antagonists
  • PDE-4 inhibitors
  • Other medications

PART 09: Segmentation by ROA

  • Inhalation
  • Oral

PART 10: Drug delivery devices market for COPD drugs

  • Market overview
  • Market segmentation by product type

PART 11: Geographical segmentation

  • Global COPD drugs market by geography 2015-2020
  • COPD drugs market in Americas
  • COPD drugs market in EMEA
  • COPD drugs market in APAC
  • COPD drugs market in China

PART 12: Market drivers

  • Increase in smoking prevalence
  • Uptake of LABA/LAMA combination therapies
  • Robust pipeline with tentative approval of drugs

PART 13: Impact of drivers

PART 14: Market challenges

  • Lack of innovation in pipeline molecules
  • Negligence toward use of controller medications
  • Low diagnosis rates

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Innovative technologies for drug delivery
  • Increased adoption of e-cigarettes and smoking cessation products
  • Emergence of ultrasonic nebulizers
  • Increase in online marketing services
  • Growing use of home healthcare devices

PART 17: Vendor landscape

  • Competitive scenario
  • Key news

PART 18: Key vendor analysis

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Novartis
  • Teva Pharmaceuticals
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Breakthrough research activities in field of COPD
  • Exhibit 03: Percentage share of pipeline molecules based on stage of development
  • Exhibit 04: Pipeline molecules based on MOA and stage of development
  • Exhibit 05: Percentage share of pipeline drugs based on MOA
  • Exhibit 06: Global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 07: Global COPD drugs market snapshot: Developed and emerging markets 2015
  • Exhibit 08: Global COPD drugs market: Key parameters driving the market 2015
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Key buying criteria for COPD drugs
  • Exhibit 11: Impact of key customer segments on global COPD drugs market
  • Exhibit 12: Segmentation of COPD drugs based on drug class
  • Exhibit 13: Percentage share of global COPD drugs by drug class based on revenue 2015
  • Exhibit 14: Global COPD drugs market: Drug class segmentation growth cycle analysis 2015
  • Exhibit 15: Combination therapies market in global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 16: Bronchodilators market in global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 17: Steroid drugs market in global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 18: Leukotriene antagonists market in global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 19: YoY growth and revenue of Daliresp 2012-2015 ($ billions)
  • Exhibit 20: Global COPD drugs market segmentation by drug class 2015
  • Exhibit 21: Segmentation of global COPD drugs market by ROA
  • Exhibit 22: Global COPD drug delivery devices market 2015-2020 ($ millions)
  • Exhibit 23: Global COPD devices market segmentation by product type
  • Exhibit 24: Percentage share of global COPD drug delivery devices by type 2015
  • Exhibit 25: Percentage share of inhalers in global COPD drug delivery devices market 2015
  • Exhibit 26: Inhalers market in global COPD drug-devices market 2015-2020 ($ millions)
  • Exhibit 27: Percentage share of nebulizers in global COPD drug delivery devices market by technology 2015
  • Exhibit 28: Nebulizers market in global COPD drug-devices market 2015-2020 ($ millions)
  • Exhibit 29: Global COPD drugs market by geography 2015-2020
  • Exhibit 30: Percentage share of global COPD drugs market by geography 2015 and 2020
  • Exhibit 31: Global COPD drugs market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 32: Global share of COPD drugs market by geography 2015
  • Exhibit 33: COPD drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 34: Prevalence rates of COPD in few countries of EMEA
  • Exhibit 35: COPD drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 36: COPD drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 37: COPD drugs market in China 2015-2020 ($ billions)
  • Exhibit 38: Global COPD drugs market: Country analysis based on revenue and growth rate
  • Exhibit 39: Drug approvals in COPD drugs market in past three years (2014-2016)
  • Exhibit 40: Few COPD drug molecules in registration stage
  • Exhibit 41: Impact of drivers
  • Exhibit 42: Controller and rescue medications for the treatment of COPD
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Key vendors ranking 2015
  • Exhibit 45: Market share of key vendors based on revenues 2015
  • Exhibit 46: Geographical presence of key vendors
  • Exhibit 47: Competitive scenario of global COPD drugs market vendors 2015-2020
  • Exhibit 48: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
  • Exhibit 49: AstraZeneca: Geographical segmentation of Symbicort 2015
  • Exhibit 50: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
  • Exhibit 51: AstraZeneca: Geographical segmentation of Pulmicort 2015
  • Exhibit 52: AstraZeneca: Metrics analysis
  • Exhibit 53: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
  • Exhibit 54: Boehringer Ingelheim: Metrics analysis
  • Exhibit 55: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
  • Exhibit 56: Geographical segmentation of Seretide/Advair 2015
  • Exhibit 57: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
  • Exhibit 58: GSK: Geographical segmentation of Flixotide/Flovent 2015
  • Exhibit 59: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
  • Exhibit 60: GSK: Geographical segmentation of Ventolin 2015
  • Exhibit 61: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
  • Exhibit 62: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
  • Exhibit 63: GSK: YoY growth and revenue of Anoro Ellipta 2014-2015 ($ millions)
  • Exhibit 64: GSK: Geographical segmentation of Anoro Ellipta 2015
  • Exhibit 65: GSK: Metrics analysis
  • Exhibit 66: Novartis: YoY revenue and growth rate of Onbrez Breezhaler/Arcapta Neohaler 2014-2015 ($ millions)
  • Exhibit 67: Novartis: YoY revenue and growth rate of Seebri Breezhaler 2013-2015 ($ millions)
  • Exhibit 68: Novartis: YoY revenue and growth rate of Ultibro Breezhaler 2013-2015 ($ millions)
  • Exhibit 69: Novartis: Metrics analysis
  • Exhibit 70: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
  • Exhibit 71: Teva Pharmaceuticals: YoY revenue and growth rate of Qvar 2013-2015 ($ millions)
  • Exhibit 72: Teva Pharmaceuticals: Metrics analysis
Back to Top